Hennion & Walsh Asset Management, Inc.
Position in MLYS — Mineralys Therapeutics, Inc.
CIK 1861642
Parsippany, NJ
Position in MLYS
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$1,877,268
-$24,152 QoQ
Shares Held
69,580
-0.9% QoQ
Ownership
0.079%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#96
of 224 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MLYS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Hennion & Walsh Asset Management, Inc. holds $200,308,891 across 60 Biotechnology names. MLYS ranks #36 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
48,019 | $11,571,138 | |
| 2 | CELC |
Celcuity Inc.
|
100,368 | $10,500,500 | |
| 3 | URGN |
UroGen Pharma Ltd.
|
276,696 | $10,182,412 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
|
171,470 | $9,741,210 | |
| 5 | SNDX |
Syndax Pharmaceuticals Inc
|
342,883 | $7,495,422 | |
| 6 | QURE |
uniQure N.V.
|
142,113 | $6,545,724 | |
| 7 | KURA |
Kura Oncology, Inc.
|
568,845 | $6,240,229 | |
| 8 | ARDX |
Ardelyx, Inc.
|
1,211,690 | $6,179,619 |
All Filings in MLYS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,877,268 | 69,580 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $1,901,420 | 70,189 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $2,517,146 | 69,362 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $2,003,996 | 52,848 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $420,715 | 31,095 | Shares | Sole | 2025-08-07 | |
| No filing history on record for this holder in this stock. | ||||||